Table 4.
Studies that reported on patients who underwent local treatment for PCLM.
| Author | Treatment | Patient number | Age | Female/male | Number of LM | Size of LM | Effectiveness | PFS | OS | Positive prognostic factors |
|---|---|---|---|---|---|---|---|---|---|---|
| Park et al.29 | RFA | 34 | 58.5 (38–78) | 15/19 | 1–4 | 0.8–3.2 | Complete ablation (100%) | NR | 14 | Single LM, LM < 2 cm, good or moderate differentiation pathological type |
| Hua et al.9 | RFA | 102 | 55.3 (38–78) | 36/66 | 2.0 (1–3) | 2.65 (0.8–5.0) | Complete ablation (94.5%) | 9 | 11.4 | Primary tumor in body/tail, LM ⩽3 cm, |
| Azizi et al.30 | TACE | 32 | 60 (49.5–67.5) | 16/16 | <5 (40.6%) ⩾5 (59.4%) |
NR | SD (71.87%) PR (9.37%) |
NR | 16 | Male patients |
| Vogl et al.31 | TACE | 69 | NR | NR | <5 (26.1%) ⩾5 (73.9%) |
NR | SD (78.26%) PR (11.59%) |
NR | 19 | NR |
| Kim et al.32 | SIRT | 33 | 64 (47–83) | 8/25 | NR | NR | SD (37%) PR (42%) |
NR | 8.1 | NR |
| Michl et al.8 | SIRT | 19 | 63 (43–77) | 9/10 | NR | NR | Objective response (47%) | 3.4 | 9.0 | NR |
| Gibbs et al.33 | SIRT | 14 | 62 (48–76) | 8/6 | NR | NR | SD (71%) PR (21%) |
5.2 | 5.5 | Resected primary PDAC |
| Kim et al.34 | SIRT | 16 | 63 (50–73) | 5/11 | NR | NR | SD (38%) PR (31%) |
NR | 12.5 | NR |
LM, liver metastases; NR, not reported; OS, overall survival; PCLM, pancreatic ductal adenocarcinoma with liver metastases; PDAC, pancreatic ductal adenocarcinoma; PFS, progression free survival; PR, partial response; RFA, radiofrequency ablation; SD, stable disease; SIRT, selective internal radiation therapy; TACE, transarterial chemoembolization.